Dr. Reddy's Laboratories Limited (ADR) (NYSE:RDY)

CAPS Rating: 4 out of 5

A global pharmaceutical company, which produces pharmaceutical ingredients and intermediates, finished dosage forms and biotechnology products and markets them globally. It conducts research in the areas of cancer, diabetes, cardiovascular disease etc.


Player Avatar SCSDogz (< 20) Submitted: 9/16/2008 11:33:31 AM : Underperform Start Price: $11.07 RDY Score: -347.92

I see bright things for this company in the future. They have a 4 biologics in the pipeline and 3 acquisitions over the last couple years. But these will not bear fruit for a while. Also RDY is still a young global company that needs to deal with growth in a profitable manner, not just for the sake of growth. They will turn to outperformers in about 2-3 years.

Featured Broker Partners